ESLA News & Events

Estrella Immunopharma presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings. The oral presentation highlighted clinical data from the Company's ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma. In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1. Notably, all patients who achieved a CR have remained in CR through the data cutoff. The median Duration of Complete Response has not yet been reached, with response durations currently ranging from 3 to 18 months. Clinical highlights also include a complete responder with Primary Central Nervous System Lymphoma, a highly aggressive NHL subtype with an extremely poor prognosis of about 30% 5-year survival rate.

Estrella Immunopharma announced that an independent Data Safety Monitoring Board has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial. Based on the safety profile observed, the DSMB recommended advancing the trial to Phase II, or the expansion phase, at the Recommended Phase II Dose. The expansion phase will further evaluate the safety and preliminary efficacy of EB103, the company's CD19-redirected Artemis T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. In the Phase I dose escalation phase, no treatment-related serious adverse events were reported. The high-dose cohort achieved a 100% complete response rate at Month 1 in all evaluable patients.

Estrella Immunopharma announced the completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected Artemis T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The study has achieved a 100% complete response rate at Month 1 in all evaluable patients treated in the second dose cohort. All patients treated are considered high-risk group who are not suitable to receive commercial CD19 products, including one with Central Nervous System lymphoma. No treatment-related serious adverse events were reported during this study phase. Following the completion of this dose cohort, a Data and Safety Monitoring Board will review the cumulative study data to evaluate the safety and efficacy of EB103, and to determine the Recommended Phase II Dose for the expansion phase. The DSMB is an independent group of experts that assesses the study's progress and makes recommendations to the trial's sponsor.